Top Markets
Coin of the day
Tricida, Inc. Tricida, Inc.

Tricida, Inc.

TCDA
Rank in Stocks #35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Share Price
$0.108
Last synced: 2023-01-23
Market Cap
$4.56M
Change (1 day)
-10.00%
Change (1 year)
0.00%
Country
US
Trade Tricida, Inc. (TCDA)

Category

EPS for Tricida, Inc. (TCDA)
EPS as of 2026 TTM: 0
According to Tricida, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Tricida, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE